Phase IIa Global Study Evaluating Rituximab for the Treatment of Pediatric Patients With Granulomatosis With Polyangiitis or Microscopic Polyangiitis.
Paul A BroganRae S M YeungGavin ClearySatyapal RangarajOzgur KasapcopurAimee O HershSuzanne C LiDusan ParipovicKenneth SchiklerAndrew ZeftClaudia BracagliaDespina EleftheriouPooneh PordeliSimone MelegaCandice JamoisJacques GaudreaultMargaret MichalskaPaul BrunettaJennifer C CooperPatricia B Lehanenull nullPublished in: Arthritis & rheumatology (Hoboken, N.J.) (2021)
In pediatric patients with GPA or MPA, RTX is well tolerated and effective, with an overall safety profile comparable to that observed in adult patients with GPA or MPA who receive treatment with RTX. RTX is associated with a positive risk/benefit profile in pediatric patients with active GPA or MPA.